Get Premium to unlock powerful stock data
VistaGen Therapeutics Inc logo

VistaGen Therapeutics Inc

$ 1.01 -0.005 (-0.49%) 02:10 PM EST
P/E:
At Loss
P/B:
2.65
Market Cap:
$ 208.59M
Enterprise V:
$ 130.10M
Volume:
316.98K
Avg Vol (2M):
1.36M
Volume:
316.98K
Market Cap $:
208.59M
PE Ratio:
At Loss
Avg Vol (2-Month):
1.36M
Enterprise Value $:
130.10M
PB Ratio:
2.65
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for VTGN (VistaGen Therapeutics Inc) from 2011 to May 26 2022. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. VistaGen Therapeutics stock (VTGN) PE ratio as of May 26 2022 is 0. More Details

VistaGen Therapeutics PE Ratio (TTM) Chart

EMBED

VistaGen Therapeutics PE Ratio (TTM) Historical Data

Total 1246
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
VistaGen Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2022-05-26At Loss 2022-03-24At Loss
2022-05-25At Loss 2022-03-23At Loss
2022-05-24At Loss 2022-03-22At Loss
2022-05-23At Loss 2022-03-21At Loss
2022-05-20At Loss 2022-03-18At Loss
2022-05-19At Loss 2022-03-17At Loss
2022-05-18At Loss 2022-03-16At Loss
2022-05-17At Loss 2022-03-15At Loss
2022-05-16At Loss 2022-03-14At Loss
2022-05-13At Loss 2022-03-11At Loss
2022-05-12At Loss 2022-03-10At Loss
2022-05-11At Loss 2022-03-09At Loss
2022-05-10At Loss 2022-03-08At Loss
2022-05-09At Loss 2022-03-07At Loss
2022-05-06At Loss 2022-03-04At Loss
2022-05-05At Loss 2022-03-03At Loss
2022-05-04At Loss 2022-03-02At Loss
2022-05-03At Loss 2022-03-01At Loss
2022-05-02At Loss 2022-02-28At Loss
2022-04-29At Loss 2022-02-25At Loss
2022-04-28At Loss 2022-02-24At Loss
2022-04-27At Loss 2022-02-23At Loss
2022-04-26At Loss 2022-02-22At Loss
2022-04-25At Loss 2022-02-21At Loss
2022-04-22At Loss 2022-02-18At Loss
2022-04-21At Loss 2022-02-17At Loss
2022-04-20At Loss 2022-02-16At Loss
2022-04-19At Loss 2022-02-15At Loss
2022-04-18At Loss 2022-02-14At Loss
2022-04-15At Loss 2022-02-11At Loss
2022-04-14At Loss 2022-02-10At Loss
2022-04-13At Loss 2022-02-09At Loss
2022-04-12At Loss 2022-02-08At Loss
2022-04-11At Loss 2022-02-07At Loss
2022-04-08At Loss 2022-02-04At Loss
2022-04-07At Loss 2022-02-03At Loss
2022-04-06At Loss 2022-02-02At Loss
2022-04-05At Loss 2022-02-01At Loss
2022-04-04At Loss 2022-01-31At Loss
2022-04-01At Loss 2022-01-28At Loss
2022-03-31At Loss 2022-01-27At Loss
2022-03-30At Loss 2022-01-26At Loss
2022-03-29At Loss 2022-01-25At Loss
2022-03-28At Loss 2022-01-24At Loss
2022-03-25At Loss 2022-01-21At Loss

VistaGen Therapeutics PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

VistaGen Therapeutics Inc logo

Business Description

Industry
Healthcare » Biotechnology » NAICS : 325412 SIC : 2834
Traded in other countries / regions
Address
343 Allerton Avenue, South San Francisco, CA, USA, 94080
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.